Home / Deep Research / Hereditary Breast and Ovarian Cancer Syndrome

Hereditary Breast and Ovarian Cancer Syndrome

1. Disease Information

2026-04-05
Falcon MONDO:0011450 Model: Edison Scientific Literature 89 citations

1. Disease Information

1.1 Concise overview (what is the disease?)

HBOC is a genetic condition characterized by increased risk for breast and ovarian cancers, often with earlier onset than sporadic cancers, and associated risks for other malignancies depending on the causal gene. HBOC is described as an autosomal dominant inherited disorder/cancer predisposition. (bouras2023overviewofthe pages 1-2, mastrodomenico2023personalizedsystemictherapies pages 1-2)

A large French cohort review states that HBOC accounts for ~10–15% of breast cancers and ~25% of ovarian cancers. (bouras2023overviewofthe pages 1-2)

1.2 Key identifiers

Not retrieved in the available evidence set: MONDO ID for HBOC, Orphanet disease ID, ICD-10/ICD-11 code, and MeSH identifier for the syndrome itself. These identifiers likely exist in aggregated resources (e.g., MONDO/Orphanet/MeSH), but were not directly extractable from the retrieved full-text snippets used here.

1.3 Synonyms and alternative names

Commonly used names in the retrieved literature include: * Hereditary Breast and Ovarian Cancer (HBOC) syndrome (mcdevitt2024emqnbestpractice pages 1-2, bouras2023overviewofthe pages 1-2) * BRCA-associated hereditary breast/ovarian cancer (tan2024brcaandbeyond pages 2-4) * Hereditary breast–ovarian cancer syndrome (kostov2022hereditarygynecologiccancer pages 5-6)

1.4 Evidence provenance (patient-level vs aggregated)

The knowledge summarized here is derived from a mixture of: * Aggregated disease-level resources (reviews, best-practice guidelines, meta-analyses) (mcdevitt2024emqnbestpractice pages 1-2, sun2024efficacyandsafety pages 1-2) * Large clinical cohorts and retrospective/prospective series (e.g., French 4,630-case panel cohort; Hungarian 513-case program; Romanian 616-case cohort; 2024 implementation cohorts) (bouras2023overviewofthe pages 1-2, nagy2024comprehensiveclinicalgenetics pages 1-2, grigore2024themoleculardetection pages 1-2, assad2024uptakeofscreening pages 1-3)

2. Etiology

2.1 Disease causal factors

Primary causal mechanism (genetic): HBOC is most frequently caused by heterozygous germline P/LP variants in BRCA1/BRCA2, tumor-suppressor genes essential for homologous recombination (HR) DNA double-strand break repair. (barili2024geneticbasisof pages 1-2, mastrodomenico2023personalizedsystemictherapies pages 2-3)

Other genes (expanded HBOC spectrum): Multigene testing increasingly identifies clinically actionable variants in other genes (e.g., PALB2, RAD51C, RAD51D, TP53, and additional moderate-penetrance genes). (bouras2023overviewofthe pages 1-2, nagy2024comprehensiveclinicalgenetics pages 1-2, mcdevitt2024emqnbestpractice pages 2-3)

2.2 Risk factors

Genetic risk factors

Environmental and demographic risk modifiers

Evidence in the retrieved set is limited for specific environmental exposures; however, a meta-analysis synthesis reported a behavioral association: ≥10 lb weight loss between ages 18–30 was associated with 34% lower breast cancer risk in one included study. (liu2023prophylacticinterventionsfor pages 16-17)

2.3 Protective factors

2.4 Gene–environment interactions

Specific gene–environment interaction evidence (e.g., formal GxE interaction terms) was not directly retrieved from the evidence set.

3. Phenotypes (clinical presentation)

3.1 Core tumor phenotypes and subtype features

Breast cancer

  • Breast cancer is the predominant phenotype; breast cancer risk increases from the mid-20s in BRCA carriers in one clinical testing summary. (list2021oncogenedxbrca1and pages 1-3)
  • Triple-negative breast cancer (TNBC): BRCA1-associated breast cancers are frequently triple-negative; one radiology review reports ~70% of BRCA1 carriers’ breast cancers are triple-negative vs ~10–20% in the general population. (katabathina2017imagingandscreening pages 1-2)

Ovarian cancer / extrauterine pelvic serous cancers

Fallopian tube precursor lesions

Male phenotypes and additional cancers

3.2 Suggested HPO terms (examples)

The retrieved evidence supports mapping at least the following phenotypes to HPO: * Breast carcinoma (from evidence of breast cancer risk) (barili2024geneticbasisof pages 1-2, list2021oncogenedxbrca1and pages 1-3) * Ovarian carcinoma / epithelial ovarian cancer (gootzen2024riskreducingsalpingectomywith pages 1-2) * High-grade serous carcinoma (ovary) (katabathina2017imagingandscreening pages 1-2, gootzen2024riskreducingsalpingectomywith pages 1-2) * Triple-negative breast cancer (katabathina2017imagingandscreening pages 1-2) * Fallopian tube carcinoma; primary peritoneal carcinoma (mastrodomenico2023personalizedsystemictherapies pages 1-2, katabathina2017imagingandscreening pages 1-2) * Male breast cancer; prostate cancer; pancreatic cancer (mastrodomenico2023personalizedsystemictherapies pages 1-2, cheng2024brca1brca2and pages 1-3) * Contralateral breast cancer (list2021oncogenedxbrca1and pages 1-3) * STIC (as precursor lesion; while not strictly an HPO phenotype, it can be captured as a pathologic finding) (gootzen2024riskreducingsalpingectomywith pages 1-2)

Frequency among affected individuals: numeric phenotype frequencies are sparse in the retrieved set beyond TNBC (~70% of BRCA1-associated breast cancers) and HGSC predominance (~90% of EOC in BRCA carriers). (katabathina2017imagingandscreening pages 1-2, gootzen2024riskreducingsalpingectomywith pages 1-2)

Quality-of-life impact: evidence is indirect; risk management is characterized as burdensome and lifelong by qualitative work, supporting QoL/psychosocial impact. (bonetti2023omicssciencesand pages 2-3)

4. Genetic / Molecular Information

4.1 Causal genes

Core causal genes and testing panel genes include: * BRCA1/BRCA2 (high penetrance) (barili2024geneticbasisof pages 1-2) * Other high/moderate penetrance genes reported in clinical panels: PALB2, TP53, RAD51C, RAD51D, BRIP1, ATM, CHEK2, and others depending on panel composition. (mcdevitt2024emqnbestpractice pages 2-3, nagy2024comprehensiveclinicalgenetics pages 1-2, bouras2023overviewofthe pages 1-2)

4.2 Pathogenic variant classes and interpretation

  • A 2024 review reports ClinVar counts (Dec 2023): ~4,300 BRCA1 and ~5,200 BRCA2 pathogenic/likely pathogenic variants; ~80% truncating, ~10% missense, ~10% CNVs. (barili2024geneticbasisof pages 2-4)
  • Variant interpretation challenges include VUS: a best-practice review notes ClinVar contains ~37% BRCA1 and ~45% BRCA2 unique variants classified as VUS, motivating functional assays to improve classification. (sirera2020novelapproachesfor pages 25-30)
  • 2024 clinical cohort work explicitly used ACMG criteria for variant interpretation in hereditary cancer panel testing. (nagy2024comprehensiveclinicalgenetics pages 2-4)

4.3 Somatic vs germline

EMQN best-practice guidance emphasizes both tumor (somatic) and germline BRCA testing to inform PARP inhibitor eligibility; ovarian tumor testing detects BRCA1/2 pathogenic variants in ~15% of patients, ~7% somatic-only. (mcdevitt2024emqnbestpractice pages 3-4)

4.4 Modifier genes / polygenic risk

EMQN notes polygenic risk scores (e.g., PRS313 in BOADICEA/CanRisk) exist but require further validation before routine use. (mcdevitt2024emqnbestpractice pages 1-2)

4.5 Epigenetic information

Noncoding mechanisms can contribute: a BRCA1 deep promoter variant (c.-107A>T) is described as causing promoter methylation (“secondary epimutation”) and reduced expression. (barili2024geneticbasisof pages 2-4)

4.6 Chromosomal abnormalities

Large rearrangements (CNVs) are an important component; EMQN requires CNV analysis at minimum and notes FFPE CNV calling challenges. (mcdevitt2024emqnbestpractice pages 3-4)

5. Environmental Information

The retrieved evidence base is limited on specific environmental toxins/infections for HBOC. Lifestyle/weight change evidence is noted under Etiology (Section 2). (liu2023prophylacticinterventionsfor pages 16-17)

6. Mechanism / Pathophysiology

6.1 Causal chain (conceptual)

  1. Germline heterozygous loss-of-function in BRCA1/BRCA2 (tumor suppressors). (barili2024geneticbasisof pages 1-2)
  2. In tumors, biallelic inactivation via loss of the remaining wild-type allele (“second hit”) produces BRCA deficiency and homologous recombination deficiency (HRD). (elze2024genomicinstabilityin pages 1-2)
  3. HRD shifts repair toward error-prone pathways, producing genomic instability scars measurable by LOH/LST/TAI signatures. (elze2024genomicinstabilityin pages 1-2, barili2024geneticbasisof pages 19-22)
  4. Resulting genomic instability contributes to carcinogenesis, notably breast cancer and HGSC; and creates vulnerabilities to platinum chemotherapy and PARP inhibitors (synthetic lethality). (mastrodomenico2023personalizedsystemictherapies pages 2-3, elze2024genomicinstabilityin pages 1-2)

6.2 Molecular pathways and terms

HR/HRD and genomic scars: JNCI 2024 defines HRD features such as large-scale state transitions, genomic loss-of-heterozygosity and telomeric allelic imbalance. (elze2024genomicinstabilityin pages 1-2)

PARP synthetic lethality: PARP inhibitors inhibit catalytic PARylation and trap PARP on DNA, converting persistent SSBs into DSBs at replication forks; HR-deficient cells cannot repair these DSBs effectively, causing cell death. (mastrodomenico2023personalizedsystemictherapies pages 2-3)

Ontology suggestions (best-effort): * GO Biological Process: homologous recombination; DNA double-strand break repair (supported by BRCA1/2 HR role) (barili2024geneticbasisof pages 1-2) * Cell Ontology (CL): mammary epithelial cell (murine mammary organoid model); fallopian tube epithelial cell (FTE) (najafabadi2023atranscriptionalresponse pages 1-2, dai2024humanfallopiantubederived pages 1-2)

6.3 Tissue-of-origin in ovarian cancer

The fallopian tube origin hypothesis is supported by STIC precursor lesions in the distal tube; a 2024 review states STICs are characterized by aberrant p53 and Ki-67 immunohistochemistry and that no precursor lesions have been identified in ovaries. (gootzen2024riskreducingsalpingectomywith pages 1-2)

7. Anatomical Structures Affected

7.1 Organ level (primary)

7.2 Tissue/cell level

7.3 Subcellular level

Mechanistically centered on nuclear DNA repair processes (homologous recombination, DNA damage response; PARP at DNA damage sites). (mastrodomenico2023personalizedsystemictherapies pages 2-3)

8. Temporal Development

8.1 Onset

  • Breast cancer risk in BRCA carriers is described as increasing from the mid-20s; ovarian risk begins in the mid-30s and rises markedly in later decades. (list2021oncogenedxbrca1and pages 1-3)

8.2 Progression

HGSC and extrauterine pelvic serous carcinomas are typically aggressive; ovarian cancer is often diagnosed late in the general population (advanced stage common), motivating preventive surgery. (inzoli2024uptakeofrisk‐reducing pages 1-2)

9. Inheritance and Population

9.1 Inheritance pattern

Autosomal dominant inheritance is repeatedly stated for HBOC. (bouras2023overviewofthe pages 1-2, mastrodomenico2023personalizedsystemictherapies pages 1-2)

9.2 Carrier prevalence / population frequency

9.3 Penetrance / risk estimates (selected)

Risk estimates vary across studies and populations; examples: * By age 70, breast cancer risk: ~60–66% BRCA1, ~55–61% BRCA2; ovarian cancer risk: ~41–58% BRCA1, ~15–16.5% BRCA2 (2024 review). (barili2024geneticbasisof pages 1-2) * Asian family study (Malaysia/Singapore) provides ethnicity- and region-specific cumulative risks by age 80 (e.g., Singapore BRCA1 breast ~57–61%, ovarian ~42%; BRCA2 breast ~43–47%, ovarian ~20%). (ho2024agespecificbreastand pages 1-2)

9.4 Founder effects and population-specific variants

  • Brazil: BRCA1 c.5266dupC accounts for 26.8% of pathogenic BRCA1 mutations in clinically selected HBOC patients; across screened Brazilian patients, frequency ~2% (120/6008). BRCA2 c.156_157insAlu accounts for 9.6% of reported BRCA2 pathogenic mutations in Brazilian literature. (ribeiro2024systematicreviewof pages 1-2)
  • Portugal: among Portuguese PV carriers, 59.5% carried three founder PVs (BRCA1 c.2037delinsCC; BRCA1 c.3331_3334del; BRCA2 c.156_157insAlu). (andaluz2024usingportuguesebrca pages 1-3)
  • Tuscany (Italy): BRCA1 c.4096+1G>A founder variant estimated MRCA ~155 generations (~3000 years) ago. (aretini2023thebrca1c.4096+1g>a pages 1-2)

10. Diagnostics

10.1 Genetic testing (current approach)

Panel testing is now routine in many settings due to cost decreases and expanded clinical actionability. EMQN 2024 provides best-practice laboratory guidance for HBOC genetic testing and emphasizes somatic + germline workflows, minimum-gene expectations (BRCA1/2 and PALB2 at minimum), and mandatory CNV analysis capability. (mcdevitt2024emqnbestpractice pages 2-3, mcdevitt2024emqnbestpractice pages 3-4)

Detection rates and yield examples: * French 13-gene panel cohort (n=4,630): 528 P/LP variants detected; BRCA1 and BRCA2 together comprised ~75% of P/LP findings; retesting BRCA-negative cases with expanded panels yielded clinically relevant findings in 5%. (bouras2023overviewofthe pages 1-2) * Hungarian hereditary cancer panel: extended panel doubled detection vs BRCA1/2-only (20.7% vs 12.1%). (nagy2024comprehensiveclinicalgenetics pages 2-4)

Technical confirmation methods: One large cohort confirmed P/LP calls via Sanger for SNVs/indels, MLPA for CNVs, and PCR/RT-PCR for complex/splice variants. (bouras2023overviewofthe pages 2-4)

10.2 Tumor testing for therapy selection

EMQN notes ovarian tumor testing identifies BRCA1/2 pathogenic variants in ~15% of patients (including ~7% somatic-only), informing PARP inhibitor eligibility. (mcdevitt2024emqnbestpractice pages 3-4)

10.3 Imaging/screening diagnostics

A radiology review notes BRCA-associated breast cancers may appear well circumscribed and can mimic benign lesions, supporting careful biopsy of detected lesions. (katabathina2017imagingandscreening pages 1-2)

11. Outcome / Prognosis

Direct survival/prognosis statistics for HBOC carriers as a group were not comprehensively retrieved; however: * BRCA-associated ovarian tumors (HGSC) are described as sensitive to platinum and PARP inhibitors, influencing outcomes. (katabathina2017imagingandscreening pages 1-2, elze2024genomicinstabilityin pages 1-2)

12. Treatment

12.1 Targeted therapy: PARP inhibitors

PARP inhibitors exploit HRD synthetic lethality in BRCA-deficient tumors. (mastrodomenico2023personalizedsystemictherapies pages 2-3)

Breast cancer (adjuvant; 2024 review reporting OlympiA outcomes): 1 year of adjuvant olaparib improved 4-year iDFS 82.7% vs 75.4% (HR 0.63) and 4-year OS 89.8% vs 86.4% (HR 0.68; p=0.009) at median 3.5-year follow-up. (tan2024brcaandbeyond pages 2-4)

Breast cancer (metastatic): * OlympiAD: olaparib vs chemotherapy median PFS 7.0 vs 4.2 months (HR 0.58); ORR 59.9% vs 28.8%; OS not statistically significant (median OS 19.3 vs 17.1 months; HR 0.90). (tan2024brcaandbeyond pages 2-4) * EMBRACA: talazoparib PFS 8.6 vs 5.6 months (HR 0.54); ORR 62.6% vs 27.2%; no significant OS benefit. (tan2024brcaandbeyond pages 2-4)

Ovarian cancer maintenance (2024 meta-analysis): pooled improvements vs placebo: PFS HR 0.398, OS HR 0.677, with increased toxicities (any-grade TEAEs RR 1.046; grade ≥3 RR 2.931). (sun2024efficacyandsafety pages 1-2)

12.2 Platinum chemotherapy

HRD/BRCA1/2 deficiency predicts increased sensitivity to platinum agents across tumor types. (elze2024genomicinstabilityin pages 1-2)

12.3 Ongoing and example clinical trials (NCT)

Interventional studies retrieved include: * NCT03344965 (Olaparib in metastatic breast cancer) (arun2024brcamutatedbreastcancer pages 6-7) * NCT03150576 (PARTNER; neoadjuvant olaparib + chemotherapy in TNBC; gBRCA wild-type population) (abraham2024thepartnertrial pages 1-4) * Risk-management/education/decision-support trials include NCT04683068, NCT06914726, NCT00673335 (beamer2019hereditarybreastand pages 1-3)

13. Prevention

Key prevention approaches are summarized in artifact-01 and include: * RRSO: mortality and ovarian cancer risk reduction with variable uptake (liu2023prophylacticinterventionsfor pages 1-2, assad2024uptakeofscreening pages 1-3, inzoli2024uptakeofrisk‐reducing pages 1-2) * Risk-reducing mastectomy: large breast cancer risk reduction; uptake variable (bertozzi2023riskreducingbreastand pages 6-7, assad2024uptakeofscreening pages 1-3) * Intensified surveillance: annual MRI with supplemental imaging per programmatic models (speiser2023primarypreventionand pages 2-3, assad2024uptakeofscreening pages 1-3)

14. Other Species / Natural Disease

No naturally occurring non-human HBOC syndrome evidence was retrieved; however, the genes and pathways are evolutionarily conserved and modeled in mice and organoids (see Model Organisms).

15. Model Organisms and Experimental Models

15.1 Mouse and organoid models

15.2 Human and patient-derived organoids

15.3 Model limitations (selected)

The HGSOC GEMM highlights limitations such as differences in mouse anatomy (ovarian bursa) and challenges modeling metastasis. (blackman2024mycissufficient pages 20-21)

Direct abstract quotes supporting key claims (selected)

Evidence gaps and notes for knowledge-base curation

  1. Ontology identifiers (MONDO/Orphanet/MeSH/ICD) for HBOC syndrome were not found in the retrieved full-text evidence and should be pulled directly from those resources.
  2. Many penetrance estimates exist; this report intentionally cites only values explicitly present in retrieved evidence. (barili2024geneticbasisof pages 1-2, ho2024agespecificbreastand pages 1-2)
  3. Environmental risk factors and formal GxE interactions were minimally represented in the retrieved evidence.

Key recent authoritative sources (with URLs and publication dates)

References

  1. (bouras2023overviewofthe pages 1-2): Ahmed Bouras, Souhir Guidara, Mélanie Leone, Adrien Buisson, Tanguy Martin-Denavit, Sophie Dussart, Christine Lasset, Sophie Giraud, Marie-Noëlle Bonnet-Dupeyron, Zine-Eddine Kherraf, Damien Sanlaville, Sandra Fert-Ferrer, Marine Lebrun, Valerie Bonadona, Alain Calender, and Nadia Boutry-Kryza. Overview of the genetic causes of hereditary breast and ovarian cancer syndrome in a large french patient cohort. Cancers, 15:3420, Jun 2023. URL: https://doi.org/10.3390/cancers15133420, doi:10.3390/cancers15133420. This article has 17 citations.

  2. (mastrodomenico2023personalizedsystemictherapies pages 1-2): Luciana Mastrodomenico, Claudia Piombino, Beatrice Riccò, Elena Barbieri, Marta Venturelli, Federico Piacentini, Massimo Dominici, Laura Cortesi, and Angela Toss. Personalized systemic therapies in hereditary cancer syndromes. Genes, 14:684, Mar 2023. URL: https://doi.org/10.3390/genes14030684, doi:10.3390/genes14030684. This article has 15 citations.

  3. (barili2024geneticbasisof pages 1-2): Valeria Barili, Enrico Ambrosini, Beatrice Bortesi, Roberta Minari, Erika De Sensi, Ilenia Rita Cannizzaro, Antonietta Taiani, Maria Michiara, Angelica Sikokis, Daniela Boggiani, Chiara Tommasi, Olga Serra, Francesco Bonatti, Alessia Adorni, Anita Luberto, Patrizia Caggiati, Davide Martorana, Vera Uliana, Antonio Percesepe, Antonino Musolino, and Benedetta Pellegrino. Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes, 15:219, Feb 2024. URL: https://doi.org/10.3390/genes15020219, doi:10.3390/genes15020219. This article has 55 citations.

  4. (mastrodomenico2023personalizedsystemictherapies pages 2-3): Luciana Mastrodomenico, Claudia Piombino, Beatrice Riccò, Elena Barbieri, Marta Venturelli, Federico Piacentini, Massimo Dominici, Laura Cortesi, and Angela Toss. Personalized systemic therapies in hereditary cancer syndromes. Genes, 14:684, Mar 2023. URL: https://doi.org/10.3390/genes14030684, doi:10.3390/genes14030684. This article has 15 citations.

  5. (bonetti2023omicssciencesand pages 2-3): G. Bonetti, G. Madeo, S. Michelini, M. Ricci, M. Cestari, S. Michelini, M. Gadler, S. Benedetti, G. Guerri, F. Cristofoli, D. Generali, C. A. Donofrio, M. Cominetti, A. Fioravanti, L. Riccio, A. Bernini, E. Fulcheri, L. Stuppia, V. Gatta, S. Cecchin, G. Marceddu, and M. Bertelli. Omics sciences and precision medicine in breast and ovarian cancer. La Clinica terapeutica, 174 Suppl 2(6):104-118, 2023. URL: https://doi.org/10.7417/ct.2023.2477, doi:10.7417/ct.2023.2477. This article has 6 citations and is from a peer-reviewed journal.

  6. (ho2024agespecificbreastand pages 1-2): Weang-Kee Ho, Nur Tiara Hassan, Sook-Yee Yoon, Xin Yang, Joanna M.C. Lim, Nur Diana Binte Ishak, Peh Joo Ho, Eldarina A. Wijaya, Patsy Pei-Sze Ng, Craig Luccarini, Jamie Allen, Mei-Chee Tai, Jianbang Chiang, Zewen Zhang, Mee-Hoong See, Meow-Keong Thong, Yin-Ling Woo, Alison M. Dunning, Mikael Hartman, Cheng-Har Yip, Nur Aishah Mohd Taib, Douglas F. Easton, Jingmei Li, Joanne Ngeow, Antonis C. Antoniou, Soo-Hwang Teo, Benita Kiat-Tee Tan, Su-Ming Tan, Veronique Kiak Mien Tan, Ern Yu Tan, Geok Hoon Lim, Alexis Khng, Gaik-Siew Ch’ng, Jamil Omar, Chee-Meng Yong, Ismail Aliyas, Rozita Abdul Malik, Suguna Subramaniam, Wee-Wee Sim, Chun Sen Lim, Saw-Joo Lee, Keng-Joo Lim, Mohamad Nasir Shafiee, Fuad Ismail Ismail, Mohd Pazudin Ismail, Mohamad Faiz Mohamed Jamli, Suresh Kumarasamy, John S.H. Low, Ahmad Muzamir Ahmad Mustafa, Mary J. Makanjang, Shahila Taib, Nellie Cheah, Chee-Kin Fong, Kean-Fatt Ho, Azura Deniel, Soo Fan Ang, Ahmad Radzi Ahmad Badruddin, and Lye-Mun Tho. Age-specific breast and ovarian cancer risks associated with germline brca1 or brca2 pathogenic variants – an asian study of 572 families. The Lancet Regional Health - Western Pacific, 44:101017, Mar 2024. URL: https://doi.org/10.1016/j.lanwpc.2024.101017, doi:10.1016/j.lanwpc.2024.101017. This article has 13 citations.

  7. (speiser2023primarypreventionand pages 2-3): Dorothee Speiser and Ulrich Bick. Primary prevention and early detection of hereditary breast cancer. Breast Care, 18:448-454, Aug 2023. URL: https://doi.org/10.1159/000533391, doi:10.1159/000533391. This article has 10 citations and is from a peer-reviewed journal.

  8. (nagy2024comprehensiveclinicalgenetics pages 1-2): Petra Nagy, János Papp, Vince Kornél Grolmusz, Anikó Bozsik, Tímea Pócza, Edit Oláh, Attila Patócs, and Henriett Butz. Comprehensive clinical genetics, molecular and pathological evaluation efficiently assist diagnostics and therapy selection in breast cancer patients with hereditary genetic background. International Journal of Molecular Sciences, 25:12546, Nov 2024. URL: https://doi.org/10.3390/ijms252312546, doi:10.3390/ijms252312546. This article has 12 citations.

  9. (mcdevitt2024emqnbestpractice pages 2-3): Trudi McDevitt, Miranda Durkie, Norbert Arnold, George J. Burghel, Samantha Butler, Kathleen B. M. Claes, Peter Logan, Rachel Robinson, Katie Sheils, Nicola Wolstenholme, Helen Hanson, Clare Turnbull, and Stacey Hume. Emqn best practice guidelines for genetic testing in hereditary breast and ovarian cancer. European Journal of Human Genetics, 32:479-488, Mar 2024. URL: https://doi.org/10.1038/s41431-023-01507-5, doi:10.1038/s41431-023-01507-5. This article has 31 citations and is from a domain leading peer-reviewed journal.

  10. (liu2023prophylacticinterventionsfor pages 17-19): Taoran Liu, Jing Yu, Yangyang Gao, Xinyang Ma, Shan Jiang, Yuanyuan Gu, and Wai-kit Ming. Prophylactic interventions for hereditary breast and ovarian cancer risks and mortality in brca1/2 carriers. Cancers, 16:103, Dec 2023. URL: https://doi.org/10.3390/cancers16010103, doi:10.3390/cancers16010103. This article has 16 citations.

  11. (bouras2023overviewofthe pages 2-4): Ahmed Bouras, Souhir Guidara, Mélanie Leone, Adrien Buisson, Tanguy Martin-Denavit, Sophie Dussart, Christine Lasset, Sophie Giraud, Marie-Noëlle Bonnet-Dupeyron, Zine-Eddine Kherraf, Damien Sanlaville, Sandra Fert-Ferrer, Marine Lebrun, Valerie Bonadona, Alain Calender, and Nadia Boutry-Kryza. Overview of the genetic causes of hereditary breast and ovarian cancer syndrome in a large french patient cohort. Cancers, 15:3420, Jun 2023. URL: https://doi.org/10.3390/cancers15133420, doi:10.3390/cancers15133420. This article has 17 citations.

  12. (liu2023prophylacticinterventionsfor pages 1-2): Taoran Liu, Jing Yu, Yangyang Gao, Xinyang Ma, Shan Jiang, Yuanyuan Gu, and Wai-kit Ming. Prophylactic interventions for hereditary breast and ovarian cancer risks and mortality in brca1/2 carriers. Cancers, 16:103, Dec 2023. URL: https://doi.org/10.3390/cancers16010103, doi:10.3390/cancers16010103. This article has 16 citations.

  13. (assad2024uptakeofscreening pages 1-3): Hadeel Assad, Maria Levitin, Nancie Petrucelli, Mark Manning, Hayley S. Thompson, Wei Chen, Hyejeong Jang, and Michael S. Simon. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic brca1/2 variants evaluated at a large urban comprehensive cancer center. Breast cancer research and treatment, 206:261-272, Apr 2024. URL: https://doi.org/10.1007/s10549-024-07283-0, doi:10.1007/s10549-024-07283-0. This article has 5 citations and is from a peer-reviewed journal.

  14. (inzoli2024uptakeofrisk‐reducing pages 1-2): Alessandra Inzoli, Serena Negri, Cristina Dell'Oro, Clarissa Costa, Liliana Marchetta, Mariaclara Boccadutri, Simona Fumagalli, Gaia Roversi, Elena Maria Sala, Chiara Celi, Valentina Rossi, and Robert Fruscio. Uptake of risk‐reducing salpingo‐oophorectomy and gynaecologic surveillance among germline brca pathogenic variants carriers. Cancer Medicine, Dec 2024. URL: https://doi.org/10.1002/cam4.70321, doi:10.1002/cam4.70321. This article has 4 citations and is from a peer-reviewed journal.

  15. (liu2023prophylacticinterventionsfor pages 16-17): Taoran Liu, Jing Yu, Yangyang Gao, Xinyang Ma, Shan Jiang, Yuanyuan Gu, and Wai-kit Ming. Prophylactic interventions for hereditary breast and ovarian cancer risks and mortality in brca1/2 carriers. Cancers, 16:103, Dec 2023. URL: https://doi.org/10.3390/cancers16010103, doi:10.3390/cancers16010103. This article has 16 citations.

  16. (bertozzi2023riskreducingbreastand pages 6-7): Serena Bertozzi, Ambrogio Londero, Anjeza Xholli, Guglielmo Azioni, Roberta Di Vora, Michele Paudice, Ines Bucimazza, Carla Cedolini, and Angelo Cagnacci. Risk-reducing breast and gynecological surgery for brca mutation carriers: a narrative review. Journal of Clinical Medicine, 12:1422, Feb 2023. URL: https://doi.org/10.3390/jcm12041422, doi:10.3390/jcm12041422. This article has 52 citations.

  17. (nagy2024comprehensiveclinicalgenetics pages 2-4): Petra Nagy, János Papp, Vince Kornél Grolmusz, Anikó Bozsik, Tímea Pócza, Edit Oláh, Attila Patócs, and Henriett Butz. Comprehensive clinical genetics, molecular and pathological evaluation efficiently assist diagnostics and therapy selection in breast cancer patients with hereditary genetic background. International Journal of Molecular Sciences, 25:12546, Nov 2024. URL: https://doi.org/10.3390/ijms252312546, doi:10.3390/ijms252312546. This article has 12 citations.

  18. (mcdevitt2024emqnbestpractice pages 3-4): Trudi McDevitt, Miranda Durkie, Norbert Arnold, George J. Burghel, Samantha Butler, Kathleen B. M. Claes, Peter Logan, Rachel Robinson, Katie Sheils, Nicola Wolstenholme, Helen Hanson, Clare Turnbull, and Stacey Hume. Emqn best practice guidelines for genetic testing in hereditary breast and ovarian cancer. European Journal of Human Genetics, 32:479-488, Mar 2024. URL: https://doi.org/10.1038/s41431-023-01507-5, doi:10.1038/s41431-023-01507-5. This article has 31 citations and is from a domain leading peer-reviewed journal.

  19. (elze2024genomicinstabilityin pages 1-2): Lisa Elze, Rachel S van der Post, Janet R Vos, Arjen R Mensenkamp, Samhita Pamidimarri Naga, Juliet E Hampstead, Emma Vermeulen, Michiel Oorsprong, Tom Hofste, Michiel Simons, Iris D Nagtegaal, Nicoline Hoogerbrugge, Richarda M de Voer, and Marjolijn J L Ligtenberg. Genomic instability in non–breast or ovarian malignancies of individuals with germline pathogenic variants in brca1/2. JNCI Journal of the National Cancer Institute, 116:1904-1913, Jul 2024. URL: https://doi.org/10.1093/jnci/djae160, doi:10.1093/jnci/djae160. This article has 7 citations.

  20. (katabathina2017imagingandscreening pages 1-2): Venkata S. Katabathina, Christine O. Menias, and Srinivasa R. Prasad. Imaging and screening of hereditary cancer syndromes. Radiologic clinics of North America, 55 6:1293-1309, Nov 2017. URL: https://doi.org/10.1016/j.rcl.2017.06.011, doi:10.1016/j.rcl.2017.06.011. This article has 7 citations and is from a peer-reviewed journal.

  21. (rahner2008hereditarycancersyndromes. pages 1-2): Nils Rahner and Verena Steinke. Hereditary cancer syndromes. Deutsches Arzteblatt international, 105 41:706-14, Oct 2008. URL: https://doi.org/10.3238/arztebl.2008.0706, doi:10.3238/arztebl.2008.0706. This article has 168 citations and is from a peer-reviewed journal.

  22. (beamer2019hereditarybreastand pages 1-3): Laura Curr Beamer. Hereditary breast and hereditary ovarian cancer: implications for the oncology nurse. Seminars in Oncology Nursing, 35:47-57, Feb 2019. URL: https://doi.org/10.1016/j.soncn.2018.12.001, doi:10.1016/j.soncn.2018.12.001. This article has 8 citations.

  23. (cheng2024brca1brca2and pages 1-3): Heather H. Cheng, Jeffrey W. Shevach, Elena Castro, Fergus J. Couch, Susan M. Domchek, Rosalind A. Eeles, Veda N. Giri, Michael J. Hall, Mary-Claire King, Daniel W. Lin, Stacy Loeb, Todd M. Morgan, Kenneth Offit, Colin C. Pritchard, Edward M. Schaeffer, Brittany M. Szymaniak, Jason L. Vassy, Bryson W. Katona, and Kara N. Maxwell. brca1, brca2, and associated cancer risks and management for male patients. JAMA Oncology, 10:1272, Sep 2024. URL: https://doi.org/10.1001/jamaoncol.2024.2185, doi:10.1001/jamaoncol.2024.2185. This article has 40 citations and is from a highest quality peer-reviewed journal.

  24. (flaum2023assessmentofpredisposition pages 31-35): NAL Flaum. Assessment of predisposition to familial non-mucinous epithelial ovarian cancer. Unknown journal, 2023.

  25. (mcdevitt2024emqnbestpractice pages 1-2): Trudi McDevitt, Miranda Durkie, Norbert Arnold, George J. Burghel, Samantha Butler, Kathleen B. M. Claes, Peter Logan, Rachel Robinson, Katie Sheils, Nicola Wolstenholme, Helen Hanson, Clare Turnbull, and Stacey Hume. Emqn best practice guidelines for genetic testing in hereditary breast and ovarian cancer. European Journal of Human Genetics, 32:479-488, Mar 2024. URL: https://doi.org/10.1038/s41431-023-01507-5, doi:10.1038/s41431-023-01507-5. This article has 31 citations and is from a domain leading peer-reviewed journal.

  26. (tan2024brcaandbeyond pages 2-4): Joshua Zhi Chien Tan, Zewen Zhang, Hui Xuan Goh, and Joanne Ngeow. Brca and beyond: impact on therapeutic choices across cancer. Cancers, 17:8, Dec 2024. URL: https://doi.org/10.3390/cancers17010008, doi:10.3390/cancers17010008. This article has 4 citations.

  27. (kostov2022hereditarygynecologiccancer pages 5-6): Stoyan Kostov, Rafał Watrowski, Yavor Kornovski, Deyan Dzhenkov, Stanislav Slavchev, Yonka Ivanova, and Angel Yordanov. Hereditary gynecologic cancer syndromes – a narrative review. OncoTargets and therapy, 15:381-405, Apr 2022. URL: https://doi.org/10.2147/ott.s353054, doi:10.2147/ott.s353054. This article has 35 citations.

  28. (sun2024efficacyandsafety pages 1-2): Guojuan Sun and Yi Liu. Efficacy and safety of parp inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials. Frontiers in Pharmacology, Sep 2024. URL: https://doi.org/10.3389/fphar.2024.1460285, doi:10.3389/fphar.2024.1460285. This article has 17 citations.

  29. (grigore2024themoleculardetection pages 1-2): Liliana-Georgiana Grigore, Viorica-Elena Radoi, Alexandra Serban, Adina Daniela Mihai, and Ileana Stoica. The molecular detection of germline mutations in the brca1 and brca2 genes associated with breast and ovarian cancer in a romanian cohort of 616 patients. Current Issues in Molecular Biology, 46:4630-4645, May 2024. URL: https://doi.org/10.3390/cimb46050281, doi:10.3390/cimb46050281. This article has 3 citations.

  30. (list2021oncogenedxbrca1and pages 1-3): G List and B BRCA. Oncogenedx: brca1 and brca2 sequencing in hereditary breast and ovarian cancer (hboc). Unknown journal, 2021.

  31. (gootzen2024riskreducingsalpingectomywith pages 1-2): TA Gootzen, M. Steenbeek, Mhd van Bommel, J. IntHout, C. Kets, Rpmg Hermens, and JA de Hullu. Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy. Familial Cancer, 23:437-445, Jun 2024. URL: https://doi.org/10.1007/s10689-024-00412-0, doi:10.1007/s10689-024-00412-0. This article has 9 citations and is from a peer-reviewed journal.

  32. (feng2023riskreducingsalpingooophorectomyamong pages 1-3): Zheng Feng, Ke Zuo, Xingzhu Ju, Xiaojun Chen, Wentao Yang, Hao Wen, Lin Yu, and Xiaohua Wu. Risk-reducing salpingo-oophorectomy among chinese women at increased risk of breast and ovarian cancer. Journal of Ovarian Research, Jun 2023. URL: https://doi.org/10.1186/s13048-023-01222-1, doi:10.1186/s13048-023-01222-1. This article has 3 citations and is from a peer-reviewed journal.

  33. (barili2024geneticbasisof pages 2-4): Valeria Barili, Enrico Ambrosini, Beatrice Bortesi, Roberta Minari, Erika De Sensi, Ilenia Rita Cannizzaro, Antonietta Taiani, Maria Michiara, Angelica Sikokis, Daniela Boggiani, Chiara Tommasi, Olga Serra, Francesco Bonatti, Alessia Adorni, Anita Luberto, Patrizia Caggiati, Davide Martorana, Vera Uliana, Antonio Percesepe, Antonino Musolino, and Benedetta Pellegrino. Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes, 15:219, Feb 2024. URL: https://doi.org/10.3390/genes15020219, doi:10.3390/genes15020219. This article has 55 citations.

  34. (sirera2020novelapproachesfor pages 25-30): N Padilla Sirera. Novel approaches for in silico identification of pathogenic variants in brca1 and brca2 hereditary breast and ovarian cancer predisposition genes. Unknown journal, 2020.

  35. (barili2024geneticbasisof pages 19-22): Valeria Barili, Enrico Ambrosini, Beatrice Bortesi, Roberta Minari, Erika De Sensi, Ilenia Rita Cannizzaro, Antonietta Taiani, Maria Michiara, Angelica Sikokis, Daniela Boggiani, Chiara Tommasi, Olga Serra, Francesco Bonatti, Alessia Adorni, Anita Luberto, Patrizia Caggiati, Davide Martorana, Vera Uliana, Antonio Percesepe, Antonino Musolino, and Benedetta Pellegrino. Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes, 15:219, Feb 2024. URL: https://doi.org/10.3390/genes15020219, doi:10.3390/genes15020219. This article has 55 citations.

  36. (najafabadi2023atranscriptionalresponse pages 1-2): Maryam Ghaderi Najafabadi, G. Kenneth Gray, Li Ren Kong, Komal Gupta, David Perera, Huw Naylor, Joan S. Brugge, Ashok R. Venkitaraman, and Mona Shehata. A transcriptional response to replication stress selectively expands a subset of brca2-mutant mammary epithelial cells. Nature Communications, Aug 2023. URL: https://doi.org/10.1038/s41467-023-40956-w, doi:10.1038/s41467-023-40956-w. This article has 6 citations and is from a highest quality peer-reviewed journal.

  37. (dai2024humanfallopiantubederived pages 1-2): Yilin Dai, Jing Xu, Xiaofeng Gong, Jinsong Wei, Yijun Gao, Ranran Chai, Chong Lu, Bing Zhao, and Yu Kang. Human fallopian tube-derived organoids with tp53 and rad51d mutations recapitulate an early stage high-grade serous ovarian cancer phenotype in vitro. International Journal of Molecular Sciences, 25:886, Jan 2024. URL: https://doi.org/10.3390/ijms25020886, doi:10.3390/ijms25020886. This article has 18 citations.

  38. (andaluz2024usingportuguesebrca pages 1-3): Stephanie Andaluz, Bojin Zhao, Siddharth Sinha, Philip Naderev Panuringan Lagniton, Diogo Alpuim Costa, Xiaofan Ding, Miguel Brito, and San Ming Wang. Using portuguese brca pathogenic variation as a model to study the impact of human admixture on human health. BMC Genomics, Apr 2024. URL: https://doi.org/10.1186/s12864-024-10311-4, doi:10.1186/s12864-024-10311-4. This article has 1 citations and is from a peer-reviewed journal.

  39. (ribeiro2024systematicreviewof pages 1-2): Andreza Amália de Freitas Ribeiro, Nilson Moreira Cipriano Junior, and Luciana Lara dos Santos. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in brazil: the current scenario. European Journal of Medical Research, Mar 2024. URL: https://doi.org/10.1186/s40001-024-01767-x, doi:10.1186/s40001-024-01767-x. This article has 11 citations and is from a peer-reviewed journal.

  40. (aretini2023thebrca1c.4096+1g>a pages 1-2): Paolo Aretini, Silvano Presciuttini, Aldo Pastore, Alvaro Galli, Sara Panepinto, Mariella Tancredi, Matteo Ghilli, Chiara Guglielmi, Diletta Sidoti, Caterina Congregati, and Maria Adelaide Caligo. The brca1 c.4096+1g>a is a founder variant which originated in ancient times. International Journal of Molecular Sciences, 24:15507, Oct 2023. URL: https://doi.org/10.3390/ijms242115507, doi:10.3390/ijms242115507. This article has 3 citations.

  41. (arun2024brcamutatedbreastcancer pages 6-7): Banu Arun, Fergus J. Couch, Jean Abraham, Nadine Tung, and Peter A. Fasching. Brca-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. British Journal of Cancer, 131:1400-1414, Aug 2024. URL: https://doi.org/10.1038/s41416-024-02827-z, doi:10.1038/s41416-024-02827-z. This article has 75 citations and is from a domain leading peer-reviewed journal.

  42. (abraham2024thepartnertrial pages 1-4): Jean E. Abraham, Karen Pinilla, Alimu Dayimu, Louise Grybowicz, Nikolaos Demiris, Caron Harvey, Lynsey M. Drewett, Rebecca Lucey, Alexander Fulton, Anne N. Roberts, Joanna R. Worley, Anita Chhabra, Wendi Qian, Anne-Laure Vallier, Richard M. Hardy, Steve Chan, Tamas Hickish, Devashish Tripathi, Ramachandran Venkitaraman, Mojca Persic, Shahzeena Aslam, Daniel Glassman, Sanjay Raj, Annabel Borley, Jeremy P. Braybrooke, Stephanie Sutherland, Emma Staples, Lucy C. Scott, Mark Davies, Cheryl A. Palmer, Margaret Moody, Mark J. Churn, Jacqueline C. Newby, Mukesh B. Mukesh, Amitabha Chakrabarti, Rebecca R. Roylance, Philip C. Schouten, Nicola C. Levitt, Karen McAdam, Anne C. Armstrong, Ellen R. Copson, Emma McMurtry, Marc Tischkowitz, Elena Provenzano, and Helena M. Earl. The partner trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature, 629:1142-1148, Apr 2024. URL: https://doi.org/10.1038/s41586-024-07384-2, doi:10.1038/s41586-024-07384-2. This article has 52 citations and is from a highest quality peer-reviewed journal.

  43. (blackman2024mycissufficient pages 1-3): Alexandra Blackman, Amy C. Rees, Robert R. Bowers, Christian M. Jones, Silvia G. Vaena, Madison A. Clark, Shelby Carter, Evan D. Villamor, Della Evans, Anthony J. Emanuel, George Fullbright, Matthew S. O’Malley, Richard L. Carpenter, David T. Long, Laura S. Spruill, Martin J. Romeo, Brian C. Orr, Kristi L. Helke, and Joe R. Delaney. Myc is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-r270h mouse model. Cancer Research Communications, 4:2525-2538, Sep 2024. URL: https://doi.org/10.1158/2767-9764.crc-24-0144, doi:10.1158/2767-9764.crc-24-0144. This article has 5 citations and is from a peer-reviewed journal.

  44. (chang2024ovariancancerpatientderived pages 1-2): Yu-Hsun Chang, Kun-Chi Wu, Kai-Hung Wang, and Dah-Ching Ding. Ovarian cancer patient-derived organoids used as a model for replicating genetic characteristics and testing drug responsiveness: a preliminary study. Cell Transplantation, Jan 2024. URL: https://doi.org/10.1177/09636897241281869, doi:10.1177/09636897241281869. This article has 8 citations and is from a peer-reviewed journal.

  45. (blackman2024mycissufficient pages 20-21): Alexandra Blackman, Amy C. Rees, Robert R. Bowers, Christian M. Jones, Silvia G. Vaena, Madison A. Clark, Shelby Carter, Evan D. Villamor, Della Evans, Anthony J. Emanuel, George Fullbright, Matthew S. O’Malley, Richard L. Carpenter, David T. Long, Laura S. Spruill, Martin J. Romeo, Brian C. Orr, Kristi L. Helke, and Joe R. Delaney. Myc is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-r270h mouse model. Cancer Research Communications, 4:2525-2538, Sep 2024. URL: https://doi.org/10.1158/2767-9764.crc-24-0144, doi:10.1158/2767-9764.crc-24-0144. This article has 5 citations and is from a peer-reviewed journal.